RxDoctor Payments Data

Nelson Medina Villanueva

Critical Care Medicine · Kissimmee, FLNPI 1790016160

Payments from drug & device makers

$14,694in general payments, 2019–2025

Across 616 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$3K
  • Boehringer Ingelheim$1K
  • Regeneron Healthcare Solutions, Inc.$937
  • Grifols USA, LLC$880
  • Actelion Pharmaceuticals US, Inc.$545
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$14,59599%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,694 in reported general payments places this provider in the 85th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$152,606
Medicare patients
502
Services billed
1,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter386$282,890
Breztri AerosphereBudesonide/Glycopyr/Formoterol118$81,188
Breo ElliptaFluticasone/Vilanterol75$36,796
Stiolto RespimatTiotropium Br/Olodaterol Hcl59$32,810
SymbicortBudesonide/Formoterol Fumarate98$29,854
EliquisApixaban26$21,364
Spiriva RespimatTiotropium Bromide18$14,418
Fluticasone-SalmeterolFluticasone Propion/Salmeterol78$6,730
BreynaBudesonide/Formoterol Fumarate37$6,110
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$5,960
Albuterol Sulfate HfaAlbuterol Sulfate237$5,396
Wixela InhubFluticasone Propion/Salmeterol50$4,836
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$2,638
Arnuity ElliptaFluticasone Furoate11$2,207
Ventolin HfaAlbuterol Sulfate22$1,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$3,240$327,854487 claims
AstraZenecaBreztri Aerosphere, Symbicort$3,087$111,042216 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$1,058$47,22877 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →